

Q&A Kiadis Pharma N.V.
Annual General Meeting of Shareholders held on 25 June 2020



SHAREHOLDER QUESTION #1: Why were the shareholders' preemptive rights not provided to, and protected for, all shareholders for the April 2020 equity raise?

SHAREHOLDER QUESTION #2: Why was an affiliate of LSP (who was indisputably a then-current shareholder as of April 2020) given the opportunity to participate in the April 2020 equity raise, but no other then-current shareholder(s) or other current shareholder affiliates were given the opportunity to participate?

KIADIS REPLIES #1 and #2: *The questions #1 and #2 will be answered jointly as these both touch upon the theme of equity raises and the position of existing shareholders therein. Since our IPO and Euronext listing, all of our equity raises have been done by means of private placements with institutional investors and we have never done a fundraising open to all our shareholders based on pre-emptive rights. Raising equity by means of a private placement with institutional investors is very typical for Dutch listed companies whereas a share offering based on pre-emptive rights is atypical. Furthermore, with reference to Dutch corporate law, corporate practice and agenda item #6 of our EGM of 29 March 2019: the Management Board may restrict or exclude pre-emptive rights upon share issue up to the authorized share capital.*

SHAREHOLDER QUESTION #3: Were any members of the Management Board or Supervisory Board involved or associated in any way, by direct or indirect ownership, management or other relationship, with any of the entities that participated in the April 2020 equity raise other than Messrs. Mark Wegter and Martijn Kleijwegt? If yes, who were they?

KIADIS REPLY #3: *No.*

SHAREHOLDER QUESTION #4: Given that the CytoSen group of shareholders have access to capital and each have sophisticated investment knowledge, and recognizing that all members of that group are sophisticated investors, can and will each be offered the same opportunities to participate in all future equity raises as was LSP in the April 2020 equity raise? If no, why not?

KIADIS REPLY #4: *We cannot comment on, or commit to, anything related to future funding. Decisions on subsequent funding will be made in the future based on circumstances at that time. Reference is also made to our reply on question #1 above regarding the customary funding routes in The Netherlands.*

SHAREHOLDER QUESTION #5: When should the Management Board and/or Supervisory Board or any of their members have known that the CHMP was going to issue a negative opinion and recommend against conditional marketing authorization for ATIR01? When did the Management Board or Supervisory Board or any of their members know?

SHAREHOLDER QUESTION #6: When should Kiadis have known that that the standard of care relative to ATIR101 had changed to include the Baltimore protocol? When did Kiadis know?

SHAREHOLDER QUESTION #7: When should Kiadis have known that revenue expectations in the initial years of European launch of ATIR101 would be minimal? When did Kiadis know?

Q&A Kiadis Pharma N.V.
Annual General Meeting of Shareholders held on 25 June 2020



KIADIS REPLIES #5, #6 and #7: *The questions #5, #6 and #7 will be answered jointly as these all seem to touch upon the theme of disclosure.*

Kiadis Pharma attaches great value to the timely and proper disclosure of material and/or price sensitive information in compliance with all relevant laws and regulations (amongst others, the EU Market Abuse Regulation). In line with such applicable legislation, Kiadis Pharma has at all times fully informed its investors / shareholders with regard to material information without delay. This is evident from, among other things, press releases and investor presentations that are available on the Kiadis Pharma website and the website of the Dutch Authority for the Financial Markets (Autoriteit Financiële Markten – “AFM”).

SHAREHOLDER QUESTION #8: *Is the Management Board and/or Supervisory Board aware of any pending or threatened litigation against Kiadis, its subsidiaries and/or its board members? If yes, what litigation is pending or has been threatened?*

KIADIS REPLY #8: *Reference is made to paragraph 3.7 (page 57) of the Registration Document that Kiadis Pharma published on 5 June, 2020 and is accessible via the Kiadis Pharma website and the website of the AFM.*

SHAREHOLDER QUESTION #9: *What percentage of the issued shares of capital stock in Kiadis is owned directly or indirectly by each member (identified by name) of the Management Board and/or by each member (identified by name) of the Supervisory Board, including in such response the identity and percentage of shares owned by each entity owned, managed or controlled, directly or indirectly, by each member of the Management Board and/or the Supervisory Board?*

KIADIS REPLY #9: *Regarding individual securities holdings in Kiadis Pharma by members of our Management Board and Supervisory Board, reference is made to the Registration Document that Kiadis Pharma published on 5 June, 2020 and is accessible via the Kiadis Pharma website and the website of the AFM and to the publicly available registers of the AFM that are accessible via the AFM website.*